A single dose recombinant AAV based CHIKV vaccine elicits robust and durable protective antibody responses in mice.

ABSTRACT:

Background

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that is responsible for Chikungunya fever, which is characterized by fever, rash, and debilitating polyarthralgia. Since its re-emergence in 2004, CHIKV has continued to spread to new regions and become a severe health threat to global public. Development of safe and single dose vaccines that provide durable protection is desirable to control the spread of virus. The recombinant adeno-associated virus (rAAV) vectors represent promising vaccine platform to provide prolonged protection with a single-dose immunization. In this study, we developed a rAAV capsid serotype 1 vector based CHIKV vaccine and evaluated its protection effect against CHIKV challenge.

Methodology

The recombinant AAV1 encoding the full-len

SUBMITTER: Zhu QX 

PROVIDER: S-EPMC11563480 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature